HK Stock Market Move | ESSEX BIO-TECH (01061) rose nearly 9% in the afternoon, and the company will showcase multiple core ophthalmic products at APAO 2026.

ESSEX BIO-TECH (01061) rose nearly 9% in the afternoon, as of the time of writing, it rose 5.83% to 4.36 Hong Kong dollars, with a turnover of 5.2576 million Hong Kong dollars. On the news front, ESSEX BIO-TECH recently announced that the group will participate in the Asia-Pacific Academy of Ophthalmology (APAO 2026) annual meeting from February 5th to 8th at the Hong Kong Convention and Exhibition Center. The group will focus on showcasing two core products, EB12-20145P (bevacizumab monoclonal antibody) and single-dose Beifushu eye drops. EB12-20145P has shown strong clinical development momentum. This project has been selected for the poster display session of the conference, where it will present clinical advances and research insights to the international ophthalmic community. It is worth noting that the company recently announced that its wholly-owned subsidiary Majeton has signed an exclusive distribution agreement with Osteopore. Osteopore is a global leader in 3D printing bioresorbable implants. The cooperation with Osteopore has set a milestone for the group in the oral market and expanded the group's product line for dental, orthodontic, and maxillofacial solutions, jointly supporting the group's pursuit of sustainable growth in the Chinese market.